Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 40
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Exp Dermatol ; 31(3): 341-348, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34676917

RESUMEN

Although cancer personalized profiling by deep sequencing (CAPP-Seq) of cell-free DNA (cfDNA) has gained attention, the clinical utility of circulating tumour DNA (ctDNA) in extramammary Paget's disease (EMPD) has not been investigated. In this study, genomic alterations in the cfDNA and tumour tissue DNA were investigated in seven patients with metastatic EMPD. CAPP-Seq revealed mutations in 18 genes, 11 of which have not yet been reported in EMPD. The variant allele frequency of some of the mutated genes reflected the disease course in patients with EMPD. In one patient, the mutation was detected even though imaging findings revealed no metastasis. In another patient with triple EMPD (genital area and both axilla), cfDNA sequencing detected the mutation in a rib metastatic lesion, which was also detected in both axilla lesions but not the genital region. Investigations of the ctDNA may be useful towards the elucidation of clonal evolution in EMPD.


Asunto(s)
Ácidos Nucleicos Libres de Células , ADN Tumoral Circulante , Enfermedad de Paget Extramamaria , Neoplasias Cutáneas , Axila , ADN Tumoral Circulante/genética , Humanos , Enfermedad de Paget Extramamaria/genética , Enfermedad de Paget Extramamaria/patología , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/patología
2.
Eur J Dermatol ; 31(1): 48-54, 2021 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-33586656

RESUMEN

BACKGROUND: The microbiome plays an important role in the tumour microenvironment (TME). OBJECTIVES: In this study, we investigated the clinical significance of the microbiota in extramammary Paget's disease (EMPD). MATERIALS & METHODS: Patients with EMPD, treated between March 2007 and September 2019 at Kumamoto University Hospital, were investigated retrospectively. Inclusion criteria included: histological diagnosis of EMPD, inspection of the bacterial culture of the cancer lesion using swab sampling, and availability of sufficient tissue in paraffin blocks for immunohistochemistry. For the latter, primary antibodies against IL-17, CD163 and ionized calcium-binding adapter molecule 1 (Iba1) were used. RESULTS: Bacterial cultures of the cancer lesion revealed that Staphylococcus aureus (S. aureus) was highly prevalent in EMPD patients, with dermal invasion or lymph node metastasis, compared to patients without these findings. Furthermore, the number of IL-17-positive cells and CD163-positive M2-like macrophages (pro-tumour macrophages) were increased in EMPD tissues with S. aureus. Moreover, the number of IL-17-producing cells in EMPD tissues positively correlated with the accumulation of CD163-positive M2-like macrophages. In addition, the percentage of CD163-positive cells within Iba-1-positive macrophages (total macrophages) was also significantly elevated in EMPD tissues with S. aureus. CONCLUSION: Based on these findings, S. aureus may exacerbate the pathological condition of EMPD via the accumulation of IL-17 and M2-like macrophages.


Asunto(s)
Interleucina-17/fisiología , Macrófagos/fisiología , Enfermedad de Paget Extramamaria/etiología , Enfermedad de Paget Extramamaria/microbiología , Staphylococcus aureus/aislamiento & purificación , Anciano , Anciano de 80 o más Años , Correlación de Datos , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
4.
J Dermatol ; 47(11): 1317-1321, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32794263

RESUMEN

Merkel cell carcinoma (MCC) is an aggressive neoplasm and patients with metastasis have poor survival outcomes. Recently, avelumab, an anti-programmed death ligand 1 (PD-L1) immune checkpoint inhibitor, was approved for first-line treatment in patients with metastatic MCC. While the administration interval of avelumab is every 2 weeks, the durable effect of a single administration of avelumab is unknown. Additionally, the effect of avelumab in pure MCC or combined MCC concurrent with non-MCC histology has not been fully elucidated. Herein, we report a case of combined MCC concurrent with squamous cell carcinoma; the patient had a complete response after a single administration of avelumab. Although the levels of avelumab were outside the detection limit within 12 weeks, a remarkable efficacy remained for more than 28 weeks after administration. Immunohistochemical analyses revealed that the expression of PD-L1 and Merkel cell polyomavirus large T antigen was almost negative or only partial in the primary tumor lesion of this patient. Conversely, thyroid transcription factor 1 (TTF-1) expression was positive in the primary MCC lesion, which is consistent with a previous report that combined MCC is positive for TTF-1 expression. In conclusion, this case study presents a rare case of TTF-1-positive combined MCC showing complete response after a single administration of avelumab.


Asunto(s)
Carcinoma de Células de Merkel , Neoplasias Cutáneas , Anticuerpos Monoclonales , Anticuerpos Monoclonales Humanizados , Carcinoma de Células de Merkel/tratamiento farmacológico , Humanos , Neoplasias Cutáneas/tratamiento farmacológico , Factor Nuclear Tiroideo 1
6.
J Dermatol ; 47(9): 1037-1040, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32515034

RESUMEN

In psoriasis, tumor necrosis factor (TNF)-α is a key pro-inflammatory cytokine that activates keratinocytes to produce other inflammatory mediators. In addition, increased serum or plasma TNF-α levels are considered to be biomarkers of psoriasis. Circulating cell-free DNA (cfDNA) originates from apoptotic or necrotic cells and reflects the severity of cellular damage. Although cfDNA has recently attracted attention as a marker in the diagnosis and prognosis of various disorders, there are few reports of its clinical implications in the field of dermatology including psoriasis. The aim of this study was to investigate whether the TNF-α gene is present in the cfDNA, and whether its levels can be utilized as a biomarker for patients with psoriasis. cfDNA was isolated from serum samples of 79 patients with psoriasis vulgaris and 29 with psoriatic arthritis. The levels of TNF-α in the cfDNA were assessed by droplet digital polymerase chain reaction. In this study, we made two novel findings. First, circulating TNF-α DNA levels in the cfDNA were significantly higher in patients with psoriasis than in healthy controls. In addition, the area under the curve was 0.91, suggesting that serum TNF-α DNA levels are effective as a diagnostic biomarker. Second, the levels of TNF-α DNA copies in the cfDNA were positively correlated with the Psoriasis Area and Severity Index (PASI) score in the group of patients with a PASI score higher than 10. Generally, a PASI score of more than 10 is defined as severe psoriasis; therefore, the levels of TNF-α DNA copies in the cfDNA could be a biomarker for severity in patients with severe psoriasis. Further studies are needed to establish serum TNF-α DNA levels as a novel biomarker of psoriasis.


Asunto(s)
Artritis Psoriásica , Ácidos Nucleicos Libres de Células , Psoriasis , Humanos , Psoriasis/diagnóstico , Psoriasis/genética , Índice de Severidad de la Enfermedad , Factor de Necrosis Tumoral alfa
8.
Med Mycol J ; 60(1): 17-21, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30814466

RESUMEN

A 66-year-old woman with diabetes who was treated with prednisolone (15 mg/day) for autoimmune hepatitis developed multiple erythematous nodules with retention of purulent fluid on her lower right limb. Candida albicans was cultured from the nodules. She was started on oral fluconazole, and the lesions subsided. However, multiple dark-red abscesses and indurations newly appeared on the left crus. Histopathological examination showed numerous branched hyphae, and tissue culture yielded a Rhizopus microsporus-related fungus. She was treated with liposomal amphotericin B combined with drainage and debridement. However, she died because of poor control of the infection and hepatic disorder.


Asunto(s)
Absceso/microbiología , Dermatomicosis/microbiología , Huésped Inmunocomprometido , Mucormicosis/microbiología , Rhizopus/aislamiento & purificación , Rhizopus/patogenicidad , Absceso/terapia , Anciano , Anfotericina B/administración & dosificación , Antifúngicos/administración & dosificación , Desbridamiento , Dermatomicosis/terapia , Drenaje , Resultado Fatal , Femenino , Hepatitis Autoinmune/tratamiento farmacológico , Humanos , Mucormicosis/terapia , Prednisolona/efectos adversos , Prednisolona/uso terapéutico
10.
J Radiat Res ; 59(6): 794-799, 2018 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-30247674

RESUMEN

The ability of topical metal-containing agents (MCAs) to enhance radiation dermatitis remains controversial. In the present study, we evaluated increases in surface doses associated with topical agents at different application thicknesses and with MCAs versus non-metal containing agents (NMCAs). We assessed two clinically available MCAs, zinc oxide ointment (ZOO) and silver sulfadiazine cream (SSDC), and eight NMCAs. Surface doses were measured using a Markus chamber placed on a polystyrene phantom. To evaluate the role of application thickness, each agent was applied to the chamber in oil-slick (<0.1-mm), 1-mm and 5-mm layers prior to irradiation of a 10 × 10 cm field with 4-, 6- and 10-MV X-ray beams. The surface dose enhancement ratio (SDER) was calculated as the ratio of the surface dose with an agent to the dose without an agent. The SDER values for the eight NMCAs, ZOO and SSDC at an oil-slick thickness were 101.6-104.6% (mean: 103.3%), 104.5% and 105.0%, respectively, using a 6-MV X-ray beam. The corresponding values at a 1-mm thickness were 196.8-237.8% (mean: 215.7%), 229.3% and 201.4%, respectively, and those at a 5-mm thickness were 342.2-382.4% (mean: 357.9%), 357.1% and 352.6%, respectively. A similar tendency was found using 4- and 10-MV X-ray beams. The lack of a significant difference in surface dose enhancement between MCAs and NMCAs, particularly when applied in oil-slick layers, suggests that MCAs do not need to be avoided or applied in a restricted manner during radiotherapy for dosimetric reasons.


Asunto(s)
Metales/farmacología , Dosificación Radioterapéutica , Administración Tópica , Relación Dosis-Respuesta en la Radiación , Humanos , Fantasmas de Imagen
11.
J Dermatol Sci ; 90(1): 52-59, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29336866

RESUMEN

BACKGROUND: Various cytokines have been indicated to be involved in the pathogenesis of systemic sclerosis (SSc). IL-22 is one of the member of IL-10 cytokine family, and several studies have implicated IL-22 signaling in the pathogenesis of autoimmune diseases. OBJECTIVES: To clarify the role of IL-22 in the regulatory mechanism of ECM expression and to determine the contribution of IL-22 to the phenotype of SSc. METHODS: The effect of IL-22 on ECM expression in normal fibroblasts was determined by using PCR array, real-time PCR and immunoblotting. microRNA expression was evaluated by real-time PCR. The expression levels of IL-22 in the skin and sera were determined by using immunohistochemical staining and ELISA. RESULTS: IL-22 significantly increased the expression of type I collagen protein without changing its mRNA levels in cultured normal human dermal fibroblast. The expression of let-7a, one of the microRNAs which have negative effect on type I collagen expression, was significantly decreased by the treatment with IL-22 in dermal fibroblasts. There was no significant difference in the serum levels of IL-22 between SSc patients and control subjects. However, the expression of IL-22 was detected in the infiltrated lymphocytes in the SSc dermis, but not in normal dermis. IL-22 receptors were expressed in both normal and SSc dermal fibroblasts to the similar extent. CONCLUSION: IL-22 expressed in infiltrated lymphocytes may stimulate the up-regulation of type I collagen protein in dermal fibroblasts via let-7a down-regulation in SSc skin.


Asunto(s)
Colágeno Tipo I/metabolismo , Dermis/metabolismo , Interleucinas/metabolismo , MicroARNs/metabolismo , Esclerodermia Sistémica/patología , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Células Cultivadas , Colágeno Tipo I/genética , Dermis/citología , Dermis/patología , Regulación hacia Abajo , Femenino , Fibroblastos , Humanos , Linfocitos/metabolismo , Masculino , Persona de Mediana Edad , ARN Mensajero/metabolismo , Esclerodermia Sistémica/sangre , Transducción de Señal/genética , Regulación hacia Arriba , Interleucina-22
12.
Rheumatology (Oxford) ; 56(1): 145-155, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27744356

RESUMEN

OBJECTIVES: The overexpression of IL-12 family cytokines is implicated in the pathogenesis of SSc, but their exact role is still unclear. The aim of this study was to investigate the regulation of extracellular matrix expression by IL-23 and its contribution to the phenotype of SSc. METHODS: The mRNA expression was determined by PCR array and real-time PCR. The expression levels of proteins were determined by immunoblotting and immunohistochemical staining. The effect of IL-23 on dermal fibrosis in vivo was examined in a mouse model of SSc induced by bleomycin injection. RESULTS: Among the IL-12 family members, IL-23 decreased expression of type I collagen protein in cultured normal dermal fibroblasts. We found that miR-4458 and miR-18a mediated the reduction of collagen expression by IL-23. On the contrary, IL-23 up-regulated type I collagen expression in SSc fibroblasts. The paradoxical effects of IL-23 in SSc fibroblasts were also mediated by the balance between miR-4458 and miR-18a expression. Moreover, we revealed that injection of IL-23 into the mouse skin accelerated skin fibrosis. CONCLUSION: This is the first study to report that the balance of two miRNAs is involved in the collagen dysregulation in SSc fibroblasts. Clarification of the regulatory mechanism of tissue fibrosis by IL-23 in SSc skin may lead to a better understanding of this disease and new therapeutic approaches.


Asunto(s)
Colágeno Tipo I/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Interleucina-12/farmacología , Interleucina-23/farmacología , Interleucina-27/farmacología , MicroARNs/efectos de los fármacos , Esclerodermia Difusa/inmunología , Animales , Antibióticos Antineoplásicos/toxicidad , Bleomicina/toxicidad , Células Cultivadas , Colágeno/metabolismo , Colágeno Tipo I/metabolismo , Factor de Crecimiento del Tejido Conjuntivo , Modelos Animales de Enfermedad , Matriz Extracelular/metabolismo , Fibroblastos/inmunología , Fibroblastos/metabolismo , Fibrosis , Humanos , Immunoblotting , Inmunohistoquímica , Interleucina-23/inmunología , Ratones , MicroARNs/genética , Fenotipo , Reacción en Cadena en Tiempo Real de la Polimerasa , Esclerodermia Difusa/genética , Esclerodermia Difusa/metabolismo , Transducción de Señal , Piel/efectos de los fármacos , Regulación hacia Arriba
13.
Eur J Dermatol ; 27(1): 20-27, 2017 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-27758763

RESUMEN

BACKGROUND: MicroRNA levels in sera or hair may potentially be useful biomarkers for various diseases. The diagnosis of nail diseases is sometimes difficult, and nail psoriasis without skin lesions is indistinguishable from nail changes caused by other diseases. OBJECTIVES: We evaluated nail microRNA levels as biomarkers for the diagnosis of psoriasis patients. MATERIALS & METHODS: MicroRNA levels were examined in psoriasis patients with (11 patients) and without (six patients) nail changes. Normal control nails were collected from 17 healthy subjects. Eight patients with other diseases who also had nail changes were also included as disease controls. RESULTS: Microarray, real-time PCR, and in situ hybridisation indicated that the expression levels of nail miR-4454 were decreased in psoriasis patients with nail changes, compared to those patients with other diseases involving nail change, or healthy subjects. The miR-4454 levels in nails showed a significant inverse correlation with the Nail Psoriasis Severity Index (NAPSI) score, suggesting that nail miR-4454 levels reflect nail condition. CONCLUSION: The levels of microRNAs in nails may be suitable biomarkers for diagnosis or evaluation of disease activity of psoriasis.


Asunto(s)
Biomarcadores/análisis , MicroARNs/análisis , Enfermedades de la Uña/diagnóstico , Enfermedades de la Uña/metabolismo , Psoriasis/diagnóstico , Estudios de Casos y Controles , Humanos , Hibridación in Situ , Análisis de Secuencia por Matrices de Oligonucleótidos , Reacción en Cadena de la Polimerasa , Índice de Severidad de la Enfermedad
14.
Exp Dermatol ; 25(2): 131-6, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26566700

RESUMEN

Long non-coding RNAs (lncRNAs) are thought to have various functions other than RNA silencing. We tried to evaluate the expression of lncRNAs in patients with systemic sclerosis (SSc) and determined whether lncRNAs controls collagen expression in dermal fibroblasts. lncRNA expression was determined by real-time PCR and in situ hybridization. Protein and mRNA levels of collagen were analysed using immunoblotting and real-time PCR. We found TSIX, one of the lncRNAs, was overexpressed in SSc dermal fibroblasts both in vivo and in vitro, which was inhibited by the transfection of transforming growth factor (TGF)-ß1 siRNA. TSIX siRNA reduced the mRNA expression of type I collagen in normal and SSc dermal fibroblasts, but not the levels of major disease-related cytokines. In addition, TSIX siRNA significantly reduced type I collagen mRNA stability, but not protein half-lives. Furthermore, we first investigated serum lncRNA levels in patients with SSc, and serum TSIX levels were significantly increased in SSc patients. TSIX is a new regulator of collagen expression which stabilizes the collagen mRNA. The upregulation of TSIX seen in SSc fibroblasts may result from activated endogenous TGF-ß signalling and may play a role in the constitutive upregulation of collagen in these cells. Further studies on the regulatory mechanism of tissue fibrosis by lncRNAs in SSc skin lead to a better understanding of the pathogenesis, new diagnostic methods by their serum levels and new therapeutic approaches using siRNAs.


Asunto(s)
Colágeno Tipo I/genética , Fibroblastos/metabolismo , ARN Largo no Codificante/fisiología , ARN Mensajero/metabolismo , Esclerodermia Sistémica/patología , Adulto , Anciano , Anciano de 80 o más Años , Colágeno Tipo I/biosíntesis , Dermis/patología , Femenino , Humanos , Lupus Eritematoso Sistémico/sangre , Masculino , Persona de Mediana Edad , Interferencia de ARN , Estabilidad del ARN , ARN Largo no Codificante/biosíntesis , ARN Largo no Codificante/sangre , ARN Largo no Codificante/genética , ARN Interferente Pequeño/farmacología , Esclerodermia Sistémica/metabolismo , Transducción de Señal/fisiología , Factor de Crecimiento Transformador beta/fisiología , Regulación hacia Arriba , Adulto Joven
15.
Biosci Trends ; 9(5): 342-9, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26559027

RESUMEN

Fms-like tyrosine kinase 3 (Flt-3) is a cytokine receptor expressed on the surface of bone-marrow progenitor of hematopoietic cells. Flt-3 ligands are produced by peripheral blood mononuclear cells, and found in various human body fluids. Flt-3 signal is involved in the regulation of vessel formation as well as B cell differentiation, suggesting that Flt-3 signal contributes to the pathogenesis of vascular abnormalities and immune dysregulation in rheumatic diseases. The aim of the present study is to examine serum Flt-3 ligand levels in patients with various rheumatic diseases, and to evaluate the possibility that serum Flt-3 ligand levels can be a useful disease marker. Sera were obtained from 20 dermatomyositis (DM) patients, 36 systemic sclerosis (SSc) patients, 10 systemic lupus erythematosus (SLE) patients, 10 scleroderma spectrum disorder (SSD) patients, 4 mixed connective tissue disease (MCTD) patients, and 12 normal subjects. Flt-3 ligand levels were determined with ELISA. Serum Flt-3 ligand levels were significantly elevated in patients with DM, SSc, SSD and MCTD compared to those in normal subjects. DM patients with elevated Flt-3 ligand levels were accompanied with significantly increased CRP levels and increased frequency of heliotrope rash than those with normal levels. In addition, SSc patients with elevated Flt-3 ligand levels showed significantly reduced frequency of nailfold bleeding. Serum Flt-3 ligand levels can be a marker of cutaneous manifestation in DM and a marker of microangiopathy in SSc. Clarifying the role of Flt-3 ligand in rheumatic diseases may lead to further understanding of these diseases and new therapeutic approaches.


Asunto(s)
Proteínas de la Membrana/sangre , Enfermedades Reumáticas/sangre , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad
16.
J Immunol ; 195(8): 3565-73, 2015 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-26355156

RESUMEN

IL-12 family cytokines are implicated in the pathogenesis of various autoimmune diseases, but their role in the regulation of extracellular matrix expression and its contribution to the phenotype of systemic sclerosis (SSc) remain to be elucidated. Among the IL-12 family members, IL-35 decreases type I collagen expression in cultured dermal fibroblasts. IL-35 consists of p35 and EBI3 subunits, and EBI3 alone could downregulate the protein and mRNA expression of type I or type III collagen in the presence or absence of TGF-ß costimulation. We found that collagen mRNA stability was reduced by EBI3 via the induction of miR-4500. The IL-35 levels in the sera or on the surface of T cells were not altered in SSc patients, while EBI3 expression was decreased in the keratinocytes of the epidermis and regulatory T cells of the dermis in SSc skin compared with normal skin, which may induce collagen synthesis in SSc dermal fibroblasts. We also found that gp130, the EBI3 receptor, was expressed in both normal and SSc fibroblasts. Moreover, we revealed that EBI3 supplementation by injection into the skin improves mice skin fibrosis. Decreased EBI3 in SSc skin may contribute to an increase in collagen accumulation and skin fibrosis. Clarifying the mechanism regulating the extracellular matrix expression by EBI3 in SSc skin may lead to better understanding of this disease and new therapeutic strategies using ointment or microinjection of the subunit.


Asunto(s)
Colágeno Tipo I/inmunología , Regulación hacia Abajo/inmunología , Interleucinas/inmunología , Receptores de Citocinas/inmunología , Esclerodermia Difusa/inmunología , Piel/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Animales , Colágeno Tipo I/genética , Receptor gp130 de Citocinas/genética , Receptor gp130 de Citocinas/inmunología , Femenino , Humanos , Interleucinas/genética , Masculino , Ratones , Persona de Mediana Edad , Antígenos de Histocompatibilidad Menor , Estabilidad del ARN/inmunología , ARN Mensajero/genética , ARN Mensajero/inmunología , Receptores de Citocinas/genética , Esclerodermia Difusa/genética , Esclerodermia Difusa/patología , Piel/patología , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/patología
17.
J Dermatol Sci ; 79(3): 268-78, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26117269

RESUMEN

BACKGROUND: Integrins, especially αv integrin (ITGAV), are thought to play central roles in tissue fibrosis and the pathogenesis of scleroderma. So far, skin phenotype of tissue-specific transgenic mice of ITGAV have not been investigated. OBJECTIVE: To investigate the role of ITGAV in the skin fibrosis, we engineered transgenic mice that overexpress ITGAV in the fibroblasts under the control of the COL1A2 enhancer promoter. METHODS: Protein or RNA expression was evaluated by real-time PCR, immunohistochemistry, immunoblotting and immunoprecipitation. RESULTS: Dermal thickness and Masson's trichrome staining were decreased in ITGAV transgenic (Tg) mice compared with wild-type (WT) mice. Protein and mRNA levels of COL1A2, COL3A1, CTGF and integrin ß3 were down-regulated in the skin of Tg mice. In addition, the cell proliferation of cultured dermal fibroblasts obtained from Tg mice skin was decreased compared to those of WT mice. FAK phosphorylation was reduced in fibroblasts cultured from Tg mice skin in comparison to WT mice fibroblasts. Integrin ß3 siRNA inhibited FAK phosphorylation levels, while FAK inhibitor reduced the expression of collagens and CTGF in mice dermal fibroblasts. CONCLUSIONS: The down-regulation of collagen or CTGF by decreased integrin ß3 and FAK phosphorylation may cause the dermal thinning in Tg mice. Lower CTGF may also result in reduced growth of Tg mice fibroblasts. Our hypothesis is that the balance between α and ß chain of integrins positively or negatively control collagen expression and dermal thickness. This study gave a new insight in the treatment of tissue fibrosis and scleroderma by balancing integrin expression.


Asunto(s)
Fibroblastos/metabolismo , Integrina alfa5/genética , Integrina alfa5/metabolismo , ARN Mensajero/metabolismo , Piel/metabolismo , Piel/patología , Animales , Proliferación Celular , Células Cultivadas , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Colágeno Tipo III/genética , Colágeno Tipo III/metabolismo , Factor de Crecimiento del Tejido Conjuntivo/genética , Factor de Crecimiento del Tejido Conjuntivo/metabolismo , Regulación hacia Abajo , Femenino , Fibrosis , Quinasa 1 de Adhesión Focal/antagonistas & inhibidores , Quinasa 1 de Adhesión Focal/metabolismo , Integrina beta3/efectos de los fármacos , Integrina beta3/genética , Integrina beta3/metabolismo , Masculino , Ratones , Ratones Transgénicos , Fosforilación/efectos de los fármacos , ARN Interferente Pequeño/farmacología
18.
Int J Dermatol ; 53(3): 300-4, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24716199

RESUMEN

BACKGROUND: Recently, single nucleotide polymorphisms (SNPs) located in microRNAs, the so-called MIRSNPs, have attracted attention for their possible involvement in the pathogenesis of various diseases. Such MIRSNPs may have a functional role, due to the alteration of microRNA function, and can be a disease marker. In this study, we evaluated the possibility that MIRSNP rs2910164 in miR-146a can be a useful marker for the diagnosis and evaluation of disease activity of polymyositis/dermatomyositis (PM/DM).Methods DNA was obtained from 25 patients with DM, 16 with clinically amyopathic DM,and three with PM, and genotyped by polymerase chain reaction (PCR). The PCR products were digested by MnlI, and the digested products were run out on a 3% agarosegel. Serum levels of miR-146a were measured by real-time PCR.Results We could not find a significant difference in the frequency of genotype distribution between controls and patients with PM/DM. However, the frequency of muscle weakness and dysphagia in patients with CC genotype was significantly higher as compared with patients with CG or GG genotype. In addition, the minimum free energy between miR-146a and its complementary strand with G allele is estimated at −26.8 kcal/mol, while that of Callele is at −24.0 kcal/mol, suggesting that the MIRSNP rs2910164 is functional. Serum miR-146a levels tended to be decreased in patients with DM with the CC genotype.Conclusions Taken together, miR-146a may be involved in the pathogenesis of PM/DM, and patients with the CC genotype are at higher risk of muscle involvement.


Asunto(s)
Dermatomiositis/genética , MicroARNs/genética , Debilidad Muscular/genética , Polimorfismo de Nucleótido Simple , Trastornos de Deglución/genética , Trastornos de Deglución/patología , Dermatomiositis/patología , Femenino , Genotipo , Humanos , Masculino , MicroARNs/sangre , Persona de Mediana Edad , Debilidad Muscular/patología , Músculo Esquelético/patología , Medición de Riesgo
19.
Arch Dermatol Res ; 306(4): 367-74, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24525843

RESUMEN

Dermatofibrosarcoma protuberans (DFSP) is an intermediate malignancy of the skin. Although COL1A1/PDGFB fusion gene was identified in the tumor cells recently, not all of the cases were positive for the fusion gene, and further researches are still needed to clarify the pathogenesis of DFSP. In this study, we investigated the role of microRNAs in the tumor. microRNA PCR array showed several microRNAs increased or decreased in DFSP in vivo compared with dermatofibroma (DF) and normal skin. Among them, the expression of miR-205 was down-regulated in DFSP compared with DF and normal skin. In situ hybridization showed that miR-205 expression was evident in dermal fibroblasts of normal skin although hardly detected in tumor cells of DF or DFSP. miR-205 inhibitor increased cell proliferation and the luciferase activity of 3'UTR of low-density lipoprotein receptor-related protein-1 (LRP-1) in cultured normal dermal fibroblasts. Immunohistochemistry showed the expression of LRP-1 was increased in DFSP tissue. Knockdown of LRP-1 suppressed cell growth and down-regulated extracellular signal-regulated kinase (ERK) phosphorylation without affecting MEK phosphorylation in cultured DFSP cells. Taken together, LRP-1 overexpression caused by the miR-205 down-regulation may play a role in the abnormal proliferation of DFSP cells via directly regulating ERK phosphorylation.


Asunto(s)
Dermatofibrosarcoma/patología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Proteína 1 Relacionada con Receptor de Lipoproteína de Baja Densidad/metabolismo , MicroARNs/biosíntesis , Neoplasias Cutáneas/patología , Proliferación Celular/genética , Células Cultivadas , Dermatofibrosarcoma/genética , Regulación hacia Abajo , Humanos , Proteína 1 Relacionada con Receptor de Lipoproteína de Baja Densidad/genética , MicroARNs/antagonistas & inhibidores , MicroARNs/genética , Fosforilación , Piel/patología , Neoplasias Cutáneas/genética
20.
Arthritis Rheumatol ; 66(6): 1636-47, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24470401

RESUMEN

OBJECTIVE: To clarify the role of interleukin-20 (IL-20) in the regulatory mechanism of extracellular matrix expression and to determine the contribution of IL-20 to the phenotype of systemic sclerosis (SSc). METHODS: Protein and messenger RNA (mRNA) levels of collagen, Fli-1, IL-20, and IL-20 receptor (IL-20R) were analyzed using polymerase chain reaction (PCR) array, immunoblotting, immunohistochemical staining, enzyme-linked immunosorbent assay, and real-time PCR. RESULTS: PCR array revealed that IL-20 decreased gene expression of α2(I) collagen (0.03-fold), Smad3 (0.02-fold), and endoglin (0.05-fold) in cultured normal dermal fibroblasts. Fli-1 protein expression was induced by IL-20 (~2-fold). The inhibition of collagen by IL-20, the induction of Fli-1 by IL-20, and the reduction of Smad3 and endoglin by IL-20 were also observed in SSc fibroblasts. Serum IL-20 levels were reduced only slightly in SSc patients but were significantly decreased in patients with scleroderma spectrum disorders (the prodromal stage of SSc) compared with those in normal subjects (111.3 pg/ml versus 180.4 pg/ml; P < 0.05). On the other hand, IL-20 mRNA expression in SSc skin was decreased compared with that in normal skin (P < 0.05), which may result in the induction of collagen synthesis in SSc dermal fibroblasts. IL-20R was expressed in normal and SSc fibroblasts. Moreover, IL-20 supplementation by injection into the skin reversed skin fibrosis induced by bleomycin in mice (~0.5-fold). CONCLUSION: IL-20 reduces basal collagen transcription via Fli-1 induction, while down-regulation of Smad3 and endoglin may cancel the effect of transforming growth factor ß in SSc fibroblasts. To confirm the therapeutic value of IL-20 and IL-20R, their function and expression in vivo should be further studied.


Asunto(s)
Interleucinas/metabolismo , Esclerodermia Difusa/metabolismo , Esclerodermia Difusa/patología , Esclerodermia Limitada/metabolismo , Esclerodermia Limitada/patología , Piel/metabolismo , Piel/patología , Adulto , Anciano , Anciano de 80 o más Años , Animales , Antígenos CD/metabolismo , Bleomicina/efectos adversos , Estudios de Casos y Controles , Células Cultivadas , Colágeno Tipo I/metabolismo , Modelos Animales de Enfermedad , Endoglina , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/metabolismo , Matriz Extracelular/patología , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Fibroblastos/patología , Fibrosis/inducido químicamente , Fibrosis/patología , Humanos , Interleucinas/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Persona de Mediana Edad , Fenotipo , Receptores de Superficie Celular/metabolismo , Transducción de Señal/fisiología , Proteína smad3/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...